BIOXCEL THERAPEUTICS INC (BTAI) Forecast, Price Target & Analyst Ratings

NASDAQ:BTAI • US09075P2048

Current stock price

1.2 USD
-0.03 (-2.44%)
At close:
1.2099 USD
+0.01 (+0.83%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOXCEL THERAPEUTICS INC (BTAI).

Forecast Snapshot

Consensus Price Target

Price Target
$13.06
+ 988.00% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.49
Revenue Estimate
356.235K
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
78.18%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$13.06
Upside
+ 988.00%
From current price of $1.20 to mean target of $13.06, Based on 11 analyst forecasts
Low
$1.01
Median
$8.16
High
$39.90

Price Target Revisions

1 Month
-12.33%
3 Months
-18.99%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for BTAI. The average price target is 13.06 USD. This implies a price increase of 988% is expected in the next year compared to the current price of 1.2.
The average price target has been revised downward by 18.99% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BTAI Current Analyst RatingBTAI Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

BTAI Historical Analyst RatingsBTAI Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
78.18%
BTAI was analyzed by 11 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about BTAI.
In the previous month the buy percentage consensus was at a similar level.
BTAI was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-02HC Wainwright & Co.Maintains Buy -> Buy
2026-03-17Rodman & RenshawInitiate Buy
2026-03-05HC Wainwright & Co.Maintains Buy -> Buy
2025-09-15HC Wainwright & Co.Reiterate Buy -> Buy
2025-09-12MizuhoMaintains Neutral -> Neutral
2025-08-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-08-19HC Wainwright & Co.Reiterate Buy -> Buy
2025-08-15HC Wainwright & Co.Maintains Buy -> Buy
2025-07-15LUCID CAPITAL MARKETSReiterate Buy -> Buy
2025-06-23HC Wainwright & Co.Maintains Buy -> Buy
2025-03-19Rodman & RenshawInitiate Buy
2025-01-30HC Wainwright & Co.Maintains Buy -> Buy
2025-01-07B of A SecuritiesDowngrade Buy -> Underperform
2025-01-06Canaccord GenuityMaintains Buy -> Buy
2024-10-21HC Wainwright & Co.Maintains Buy -> Buy
2024-09-06HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-30Canaccord GenuityMaintains Buy -> Buy
2024-08-09UBSMaintains Neutral -> Neutral
2024-08-08HC Wainwright & Co.Maintains Buy -> Buy
2024-06-27Canaccord GenuityMaintains Buy -> Buy
2024-05-10HC Wainwright & Co.Reiterate Buy -> Buy
2024-04-23HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-18HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-14Canaccord GenuityMaintains Buy -> Buy
2024-03-13B of A SecuritiesMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.49
Revenue Estimate
356.235K
Revenue Q2Q
112.04%
EPS Q2Q
67.02%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
19.61%
Revenue (3 Months)
-4.75%
EPS (1 Month)
21.35%
EPS (3 Months)
32.87%

Next Earnings Summary

BTAI is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.49 USD and the consensus revenue estimate is 356.24K USD.
The next earnings revenue estimate has been revised downward by 4.75% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
BTAI revenue by date.BTAI revenue by date.
1.38M
263.16%		2.266M
64.20%		642K
-71.67%		1.912M
197.82%		19.314M
910.15%		50.133M
159.57%		182.38M
263.79%		407.39M
123.37%		603.33M
48.10%		736.34M
22.05%		880.26M
19.55%
EBITDA
YoY % growth
BTAI ebitda by date.BTAI ebitda by date.
-167.301M
-5.01%		-64.495M
61.45%		-49.967M
22.53%		-49.977M
-0.02%		-61.405M
-22.87%		-55.181M
10.14%		-54.162M
1.85%		138.11M
354.99%		305.9M
121.49%		418.91M
36.94%		543.86M
29.83%
EBIT
YoY % growth
BTAI ebit by date.BTAI ebit by date.
-167.619M
-4.99%		-64.804M
61.34%		-50.267M
22.43%		-44.848M
10.78%		-66.032M
-47.23%		-55.692M
15.66%		-55.182M
0.92%		137.09M
348.43%		304.88M
122.39%		417.89M
37.07%		542.84M
29.90%
Operating Margin
BTAI operating margin by date.BTAI operating margin by date.
-12,146.30%-2,859.84%-7,829.75%-2,345.63%-341.89%-111.09%-30.26%33.65%50.53%56.75%61.67%
EPS
YoY % growth
BTAI eps by date.BTAI eps by date.
-98.40
-4.03%		-25.97
73.61%		-6.71
74.16%		-3.25
51.57%		-1.98
39.12%		-0.82
58.76%		-0.64
21.25%		1.50
333.33%		3.13
108.84%		4.01
28.01%		4.86
21.12%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.49
67.02%		-0.37
84.80%		-0.33
85.03%		-0.37
35.81%		-0.50
-1.34%		-0.47
-26.58%		-0.50
-54.06%		-0.53
-41.51%
Revenue
Q2Q % growth		356.235K
112.04%		360.57K
200.48%		354.45K
261.68%		495.975K
93.74%		N/AN/AN/AN/A
EBITDA
Q2Q % growth		-11.171M
-11.45%		-13.257M
15.57%		-12.999M
5.86%		-12.459M
-24.81%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-10.138M
-0.38%		-11.563M
27.06%		-11.076M
21.08%		-10.8M
-5.04%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BTAI Yearly Revenue VS EstimatesBTAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
BTAI Yearly EPS VS EstimatesBTAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60 -80

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
23.38%
EPS Next 5 Year
17.33%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
345.68%
Revenue Next 5 Year
272.73%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-1.38%
EBIT Next 5 Year
35.74%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BIOXCEL THERAPEUTICS INC / BTAI Forecast FAQ

What do analysts expect the price target to be for BIOXCEL THERAPEUTICS INC (BTAI)?

11 analysts have analysed BTAI and the average price target is 13.06 USD. This implies a price increase of 988% is expected in the next year compared to the current price of 1.2.

Can you provide the upcoming earnings date for BIOXCEL THERAPEUTICS INC?

BIOXCEL THERAPEUTICS INC (BTAI) will report earnings on 2026-05-11.

What are the consensus estimates for BIOXCEL THERAPEUTICS INC (BTAI) next earnings?

The consensus EPS estimate for the next earnings of BIOXCEL THERAPEUTICS INC (BTAI) is -0.49 USD and the consensus revenue estimate is 356.24K USD.

Can you provide the analyst count for BIOXCEL THERAPEUTICS INC stock?

The number of analysts covering BIOXCEL THERAPEUTICS INC (BTAI) is 11.